NeuroSense Therapeutics Warrant
NRSNW
4 hedge funds and large institutions have $43.9K invested in NeuroSense Therapeutics Warrant in 2024 Q4 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 4 reducing their positions, and closing their positions.
156% more capital invested
Capital invested by funds: $17.1K → $43.9K (+$26.7K)
0% more funds holding
Funds holding: 4 → 4 (0)
0.18% less ownership
Funds ownership: 0.72% → 0.54% (-0.18%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 4
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$685 |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$606 |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$28 |
| 4 |
CS
Clear Street
New York
|
-$27 |
NRSNW Hedge Fund Activity: Q4 2024 in Review
4 of the 7,612 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics Warrant (NRSNW) for Q4 2024, worth a combined $43.9K — up 156% from $17.1K a quarter earlier.
Fund positioning in NRSNW was balanced in Q4 2024: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 4 trimmed.
The largest seller was Citadel Advisors, cutting an estimated $685.
- 4 institutional investors held NeuroSense Therapeutics Warrant (NRSNW) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $43.9K of NeuroSense Therapeutics Warrant stock for Q4 2024, up 156% quarter-over-quarter.
- 0 funds opened new NeuroSense Therapeutics Warrant positions in Q4 2024 and 0 closed out.
- The largest NeuroSense Therapeutics Warrant seller in Q4 2024 was Citadel Advisors, an estimated $685 sold.
Based on aggregated 13F filings for Q4 2024.